Angiotensin II Receptor Blocker Candesartan Cilexetil,but Not Hydralazine Hydrochloride,Protects Against Mouse Cardiac Enlargement Resulting From Undernutrition In Utero

Abstract

Epidemiologic studies have shown that malnutrition in utero is a risk factor for cardiovascular disease (CVD) in adulthood. Recently, we reported a mouse animal model of 30% maternal caloric reduction, in which adult offspring (undernourished [UN] offspring) showed a significant increase in cardiac remodeling-associated parameters, such as cardiac enlargement (CE) and coronary perivascular fibrosis (CPVF), as risk factors for CVD. To investigate the possible involvement of the angiotensin system, an angiotensin II receptor antagonist, candesartan cilexetil, or a nonspecific vasodilator, hydralazine hydrochloride, was administrated via a subcutaneously implanted miniosmotic pump to the UN offspring from 9 to 17 weeks after birth. Administration of candesartan cilexetil, but not hydralazine hydrochloride, significantly protected against CE. While administration of not only candesartan cilexetil but also hydralazine hydrochloride prevented an augmentation of CPVF. The angiotensin system seems to make a critical contribution to the developmental origins of cardiac enlargement.

Keywords

DOHaD pregnancy nutrition cardiac remodeling.

Get full access to this article

View all access options for this article.

References

Barker DJ , Gluckman PD , Godfrey KM , Harding JE , Owens JA , Robinson JS Fetal nutrition and cardiovascular disease in adult life. Lancet. 1993;341(8850):938-941.

Gluckman PD , Hanson MA Living with the past: evolution, development, and patterns of disease. Science. 2004; 305(5691):1733-1736.

Gluckman PD , Hanson MA The Fetal Matrix-Evolution, Development and Disease. Cambridge : Cambridge University Press; 2005 .

Brennan KA , Olson DM , Symonds ME Maternal nutrient restriction alters renal development and blood pressure regulation of the offspring. Proc Nutr Soc. 2006;65(1):116-124.

Ford SP , Hess BW , Schwope MM , et al. Maternal undernutrition during early to mid-gestation in the ewe results in altered growth, adiposity, and glucose tolerance in male offspring . J Anim Sci. 2007;85(5):1285-1294.

Choi GY , Tosh DN , Garg A. , Mansano R. , Ross MG , Desai M. Gender-specific programmed hepatic lipid dysregulation in intrauterine growth-restricted offspring. Am J Obstet Gynecol. 2007;196(5):477.e1-477.e7.

Thompson NM , Norman AM , Donkin SS , et al. Prenatal and postnatal pathways to obesity: different underlying mechanisms, different metabolic outcomes. Endocrinology. 2007; 148(5):2345-2354.

Yura S. , Itoh H. , Sagawa N. , et al. Role of premature leptin surge in obesity resulting from intrauterine undernutrition. Cell Metab. 2005;1(6):371-378.

Yura S. , Itoh H. , Sagawa N. , et al. Neonatal exposure to leptin augments diet-induced obesity in leptin-deficient Ob/Ob mice. Obesity (Silver Spring). 2008;16(6):1289-1295.

10.

Gluckman PD , Hanson MA The developmental origins of the metabolic syndrome. Trends Endocrinol Metab. 2004; 15(4):183-187.

11.

Kawamura M. , Itoh H. , Yura S. , et al. Undernutrition in utero augments systolic blood pressure and cardiac remodeling in adult mouse offspring: possible involvement of local cardiac angiotensin system in developmental origins of cardiovascular disease. Endocrinology. 2007;148(3):1218-1225.

12.

Unger T. Blood pressure lowering and renin-angiotensin system blockade. J Hypertens Suppl. 2003;21(6):S3-S7.

13.

Rasch R. , Skriver E. , Woods LL The role of the RAS in programming of adult hypertension. Acta Physiol Scand. 2004;181(4):537-542.

14.

Varagic J. , Frohlich ED Local cardiac renin-angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol. 2002;34(11):1435-1442.

15.

Berecek KH , Reaves P. , Raizada M. Effects of early perturbation of the renin-angiotensin system on cardiovascular remodeling in spontaneously hypertensive rats. Vascul Pharmacol . 2005;42(3):93-98.

16.

See S, Stirling AL. Candesartan cilexetil: an angiotensin II-receptor blocker. Am J Health Syst Pharm. 2000;57(8):739-746. 17. Tokuda K, Kai H, Kuwahara F, et al. Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension. 2004;43(2):499-503.

17.

Okazaki H. , Minamino T. , Tsukamoto O. , et al. Angiotensin II type 1 receptor blocker prevents atrial structural remodeling in rats with hypertension induced by chronic nitric oxide inhibition . Hypertens Res. 2006;29(4):277-284.

18.

Yamamoto E. , Kataoka K. , Yamashita T. , et al. Role of xanthine oxidoreductase in the reversal of diastolic heart failure by candesartan in the salt-sensitive hypertensive rat. Hypertension. 2007;50(4):657-662.

19.

Asakawa M. , Takano H. , Nagai T. , et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation. 2002;105(10):1240-1246.

20.

Ishiguro K. , Kadomatsu K. , Kojima T. , et al. Syndecan-4 deficiency leads to high mortality of lipopolysaccharide-injected mice. J Biol Chem . 2001;276(50):47483-47488.

21.

Matoba N. , Doyama N. , Yamada Y. , Maruyama N. , Utsumi S. , Yoshikawa M. Design and production of genetically modified soybean protein with anti-hypertensive activity by incorporating potent analogue of ovokinin(2-7). FEBS Lett. 2001;497(1):50-54.

22.

Nicoletti A. , Michel JB Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc Res. 1999;41(3):532-543.